



Iconovo updates its long-term financial targets – expects strong revenue growth with a high margin
PRESS RELEASE
Iconovo expects to reach sales of SEK 250 million in 2027. The target for the operating profit in the same year is SEK 125 million, resulting…

Iconovo uppdaterar sina långsiktiga finansiella mål – ser stark intäktsökning med hög marginal
PRESSMEDDELANDE
Iconovo tillkännager idag sina femårsmål för verksamheten. År 2027 räknar bolaget med att uppnå en försäljning om 250 miljoner…


Shorter time to market with a customized inhaler platform
In the next few years, the patents will expire for many best-selling inhaled medicines. As for other pharmaceuticals, there is a huge market…

Reduce development costs with an innovative inhaler partner
We bring inhalation expertise to your business
In any pharmaceutical development project, cost-efficiency is crucial. It is important…

Reduce development risk with the right expertise
Inhalation is often used to treat conditions in the respiratory system and the lungs, for example COPD or asthma. The drug reaches its target…

Meet us at Bio International, San Diego , June 13-16
In June, Iconovo will attend the conference Bio International to meet new customers and partners. Roger Lassing, VP Business Development, is happy to book…



Interim Report for Q1 2022 available in English
The abbreviated Interim Report for January to March 2022 is now avaialble in English.
Read it here
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 70 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
VP Business Development
Roger Lassing
Mail: roger.lassing@iconovo.se
CEO
Johan Wäborg
Mail: johan.waborg@iconovo.se